Kainic acid hydrate

Cat. No.: HY-N2309A CAS No.: 58002-62-3 Molecular Formula: $C_{10}H_{17}NO_5$ 231.25 Molecular Weight: Target: mGluR

Pathway: GPCR/G Protein; Neuronal Signaling

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

Product Data Sheet

BIOLOGICAL ACTIVITY

Description

Kainic acid hydrate is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid hydrate induces seizures^{[1][2]}.

In Vivo

Kainic acid hydrate (5 mg/kg; i.p.; hourly at least 3 h until status epilepticus) induces seizures in rats^[1]. The kainic acid induced seizures model is a good tool to study temporal lobe epilepsy. The model can be reproduced in a variety of species through either systemic, intrahippocampal or intra-amygdaloid administrations. The systemic Kainic acid administration induced model is similar with human temporal lobe epilepsy (TLE)^{[4][6]}. Kainic acid (5 nmoles, injections into the neostriatum, substantia nigra or cerebellum) shows that more than half of the compound disappeared from the injection site and the brain by 1/2 hour post injection, and less than radioactivity of 7 pmol/mg of tissue were found in other areas^[3].

Induction of epilepsy model^[5]

Background

Kainic acid, an analog of L-glutamate and an ionotropic KA receptor agonist, can damage hippocampal pyramidal neurons.

Specific Mmodeling Methods

Mice: C57BL/6J • male • 7 weeks old • 22 g body weight Administration: 10 μg in 5 μL • i.c.v.

Note

- (1) The right lateral brain ventricle is localized with a stereotactic instrument.
- (2) After the operation, skin was sutured, and keep the mice under a warming place until they wake up.
- (3) 48 hours after lateral ventricle injection, the mice are anaesthetized using Isoflurane and then sequentially intracardially perfused with saline and PFA (4%, 30 mL). Rapidly remove The mouse brain processed for paraffin embedding or frozen sections.

Modeling Record

Electroencephalogram (EEG) recording: Had higher local maximal amplitude and reduced spike frequency compared to the control group.

Histology analysis: Showed Triangulated pyknotic nuclei and cytoplasmic shrinkage in the hippocampal neuron, and induced neuronal loss.

Correlated Product(s): Sitagliptin (HY-13749)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8 weeks, 200-250 g male adult Wistar rats ^[1]
Dosage:	5 mg/kg
Administration:	I.p.; hourly at least 3 h until status epilepticus
Result:	Induced seizures in rats.

CUSTOMER VALIDATION

- Nat Neurosci. 2023 Apr;26(4):542-554.
- Nat Chem Biol. 2024 Jun 19.
- J Neuroinflammation. 2021 May 11;18(1):112.
- Biochem Biophys Res Commun. 2021 Feb 8;545:195-202.
- Brain Res. 12 August 2022, 148052.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Cincioğlu-Palabiyik M, et al. Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats. Neuroreport. 2017 Sep 27;28(14):903-909.

[2]. Wang Q, et al. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol. 2005;31(1-3):3-16.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA